Table 2:
Description of azithromycin exposure any time after HCT for 237 patients*
| Number of azithromycin exposures per patient† | N (%) |
|---|---|
| 1 | 165 (52.2%) |
| 2 | 60 (19%) |
| 3 | 12 (3.8%) |
| Characteristics of 1st exposure | |
| Duration (days, median, IQR) | 230 [7;847] |
| Before BOS | 66 (20.9%) |
| At or after BOS | 167 (52.9%) |
| Both before and after BOS | 4 (1.3%) |
| Characteristics of 2nd exposure | |
| Duration (days, median, IQR) | 244.5 [90;884.8] |
| Before BOS | 7 (2.2%) |
| At or after BOS | 64 (20.2%) |
| Both before and after BOS | 1 (0.32%) |
| Characteristics of 3rd exposure | |
| Duration (days, median, IQR) | 191.5 [69.2;783.2] |
| Before BOS | 0 (0%) |
| At or after BOS | 12 (3.8%) |
| Both before and after BOS | 0 (0%) |
*
10 patients received azithromycin only before BOS for a median time of 7 days among the 237 patients who received azithromycin during the study period;
†
a single exposure of azithromycin was defined by azithromycin intake with a start and end date; the minimum duration of the 1st exposure after BOS was 7 days. A subsequent azithromycin exposure was considered if there was at least one day free of intake between two courses of azithromycin.
BOS: bronchiolitis obliterans syndrome; IQR: interquartile range